-
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
van Lierop, Z. Y. G., Wieske, L., Koel-Simmelink, M. J. A., Chatterjee, M., Dekker, I., Leurs, C. E., Willemse, E. A. J., Moraal, B., Barkhof, F., Eftimov, F., Uitdehaag, B. M. J., Killestein, J. & Teunissen, C. E., Jan 2022, In: Multiple sclerosis (Houndmills, Basingstoke, England). 28, 1, p. 102-110 9 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Response to letter ‘Lymphocyte counts and the risk of COVID-19 in people with MS’
Loonstra, F. C., van Kempen, Z. L. E., Strijbis, E. M., Killestein, J., Hoitsma, E. & Mostert, J. P., Sept 2021, In: Multiple sclerosis (Houndmills, Basingstoke, England). 27, 10, p. 1626-1627 2 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Natalizumab discontinuation in a Dutch real-world cohort
Coerver, E. M. E., Wessels, M. H. J., van Lierop, Z. Y. G., van Kempen, Z. L. E., Killestein, J. & Strijbis, E. M. M., 1 Jul 2021, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 52, p. 102974 102974.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
- All publications